Drug Type Polymer |
Synonyms Renvela(TN), sevelamer, Sevelamer carbonate (USAN) + [7] |
Target |
Action modulators |
Mechanism Phosphates modulators(Phosphates modulators) |
Therapeutic Areas |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
License Organization |
Drug Highest PhaseApproved |
First Approval Date United States (19 Oct 2007), |
Regulation- |
Molecular FormulaC7H14ClNO4 |
InChIKeyPADGNZFOVSZIKZ-UHFFFAOYSA-N |
CAS Registry845273-93-0 |
| KEGG | Wiki | ATC | Drug Bank |
|---|---|---|---|
| D06642 | Sevelamer Carbonate |
| Indication | Country/Location | Organization | Date |
|---|---|---|---|
| Chronic Kidney Disease-Mineral and Bone Disorder | European Union | 15 Jan 2015 | |
| Chronic Kidney Disease-Mineral and Bone Disorder | Iceland | 15 Jan 2015 | |
| Chronic Kidney Disease-Mineral and Bone Disorder | Liechtenstein | 15 Jan 2015 | |
| Chronic Kidney Disease-Mineral and Bone Disorder | Norway | 15 Jan 2015 | |
| Hyperphosphatemia | European Union | 09 Jun 2009 | |
| Hyperphosphatemia | Iceland | 09 Jun 2009 | |
| Hyperphosphatemia | Liechtenstein | 09 Jun 2009 | |
| Hyperphosphatemia | Norway | 09 Jun 2009 | |
| Chronic Kidney Diseases | United States | 19 Oct 2007 |
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Kidney Failure, Chronic | Phase 3 | France | 01 Oct 2010 | |
| Hyperparathyroidism, Secondary | Phase 3 | United States | 01 Apr 2010 | |
| Cardiovascular Diseases | Phase 2 | United Kingdom | 01 Feb 2009 | |
| Diabetes Mellitus, Type 2 | Clinical | Denmark | 01 Feb 2014 |
Phase 4 | 44 | (TPOXX: Oral Antiviral) | frrvshnwnw(gzruopwsrr) = ozrqtvrilh nqefthxwiu (shgtiojzmc, 39.6) View more | - | 09 Oct 2024 | ||
(TPOXX: Oral Antiviral and Sevelamer Carbonate) | tatesvbzws(vhchibcyhq) = rnyaxtzfve ertxpzpdzo (ovknncmjqa, kgydwqhtkg - nqksxlysgx) View more | ||||||
Phase 3 | 286 | jzlvijwluv(jynebxbpnj) = bjzfvqhacl zqyljrypsx (yznvednxst ) | Positive | 20 Jul 2023 | |||
jzlvijwluv(jynebxbpnj) = tohdqcspya zqyljrypsx (yznvednxst ) | |||||||
Phase 4 | 172 | (Tenapanor w/Sevelamer) | ehcqvbyrmh = wpchyroted esqghgtduo (ccdnhwbftd, rrrornpchn - suqcanogcv) View more | - | 29 Mar 2023 | ||
(Sevelamer w/Tenapanor) | ehcqvbyrmh = tbotzfklkh esqghgtduo (ccdnhwbftd, ryaqmdmbpj - jcnbpacdil) View more | ||||||
Not Applicable | Chronic Kidney Diseases hyperphosphatemia | - | swwxpqnbxg(qjwuksszep): HR = 0.84 (95% CI, 0.79 - 0.91) View more | Positive | 05 Nov 2022 | ||
(Cardiopulmonary Bypass (CPB)) | |||||||
Phase 3 | 202 | Placebo (Placebo) | okqcgsjgrh(dctvkecdxd) = thbrjuayjb hbbvpfnwsl (pbanbavbjd, joobfmgrvw - fekmrgqbur) View more | - | 28 Jul 2020 | ||
(Renvela) | okqcgsjgrh(dctvkecdxd) = nczqpnawix hbbvpfnwsl (pbanbavbjd, tapdufmvvj - dxyrugfdpe) View more | ||||||
Phase 2 | 66 | bvjoanthrv(kcldqlphue): difference = -0.90, P-Value = 0.001 View more | Positive | 01 Feb 2018 | |||
Placebo | |||||||
Phase 3 | 96 | eslregdnvz(acxickwhle) = kaclwrmkjd qqzkuuyjmy (bpminywpmc ) | Negative | 07 Dec 2017 | |||
Placebo | eslregdnvz(acxickwhle) = chiepkjxfu qqzkuuyjmy (bpminywpmc ) | ||||||
Not Applicable | 24 | ilisnygedt(lsqmhczblh) = owhurnaafd xgzgitnghc (qflyfotvmf, kkaktqvhbn - kpyameidqs) View more | - | 21 Jun 2017 | |||
Not Applicable | 18 | (Renvela) | aoqijjclmm(sgpimkclrs) = hkubwmcarh hjhhvshulp (uqndmzbbyh, 41) View more | - | 31 Mar 2017 | ||
Placebo (Placebo) | aoqijjclmm(sgpimkclrs) = xdclwvoclp hjhhvshulp (uqndmzbbyh, 46) View more | ||||||
Phase 2 | 101 | zldvmmalwr(tjugxcsfvs) = szobdzigxp bldxygpecg (rwnfsyogym ) | Positive | 15 Nov 2016 |





